Vesper Bio

Executive Summary

Vesper Bio is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, founded in 2020 with a focus on neurodegenerative diseases. The company is pioneering the development of oral small molecules and antibodies that selectively target the protein sortilin to modulate pathological protein-protein interactions. Its lead program is directed at frontotemporal degeneration linked to progranulin mutations (FTD-GRN), a rare and devastating form of dementia. By addressing the underlying mechanisms of neurodegeneration, Vesper Bio aims to transform the treatment landscape for these conditions. The company's approach leverages deep expertise in protein biology and small molecule design to create disease-modifying therapies with potential applications beyond FTD-GRN, including other neurodegenerative disorders. As a private entity, Vesper Bio is poised to advance its pipeline through clinical development, supported by its strong scientific foundation and strategic location in the European biotech hub.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical trial initiation for lead FTD-GRN program70% success
• Q2 2026Regulatory clearance (CTA/IND) for lead candidate80% success
• Q4 2026Potential partnership or collaboration deal for sortilin platform40% success